首页> 美国卫生研究院文献>Cancer Medicine >Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long‐term multicenter cohort study
【2h】

Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long‐term multicenter cohort study

机译:日本肾移植后累积癌症发病率和死亡率:长期多中心队列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Kidney transplantation is the most promising treatment to improve mortality and life quality in end‐stage kidney disease; however, cancer remains a leading cause of death. Several factors including immunosuppressants might be associated with a gradual increase in cumulative cancer incidence after kidney transplantation. Risk factors for cancer and overall and cancer‐specific survival were analyzed in 1973 kidney transplant recipients from three study institutions in Japan. The 5‐, 10‐, 20‐, and 30‐year overall and cancer‐specific survival rates were 93.3%, 88.4%, 78.0%, and 63.6% and 99.4%, 98.0%, 95.3%, and 91.7%, respectively. The overall survival rate was significantly higher and the graft survival rate was significantly lower in recipients without cancer than in those with cancer. Older recipient age, longer dialysis duration before kidney transplantation, and history of transfusion were significant predictors of cancer. Dialysis duration before kidney transplantation was a prognostic factor of overall survival rate. Regarding cancer‐specific survival rates, older recipient age and dialysis duration before kidney transplantation were prognostic factors of worse cancer‐specific survival rates. The type of immunosuppressant was not associated with an increased cancer rate. Aggressiveness of immunosuppressant regimens or potent immunosuppressants might improve graft survival rate while inducing de novo cancer after kidney transplantation. Older age and longer dialysis duration before kidney transplantation were risk factors of cancer‐specific survival rate.
机译:肾移植是最有前途的治疗,以提高肾病终期肾病中的死亡率和生活质量;然而,癌症仍然是死亡的主要原因。包括免疫抑制剂的几个因素可能与肾移植后累积癌症发病率的逐渐增加有关。 1973年,在日本三个研究机构的1973年肾移植受者分析了癌症和总体和癌症特异性生存的危险因素。总体和癌症特异性生存率的5-,10-,20-和30年,分别为93.3%,88.4%,78.0%和63.6%,分别为99.4%,98.0%,95.3%和91.7%。整体存活率明显升高,接枝存活率在没有癌症的受者中显着低于癌症。年龄较大的受访者年龄,肾移植前更长的透析持续时间,输血史是癌症的显着预测因子。肾移植前的透析持续时间是总存活率的预后因素。关于癌症特异性的存活率,肾移植前的较差的持续因子是癌症特异性更严重的存活率的预后因素。免疫抑制剂的类型与增加的癌症率没有相关。免疫抑制方案或有效免疫抑制剂的侵蚀性可能会改善移植物存活率,同时诱导肾移植后诱导De Novo癌症。肾移植患者患有癌症特异性存活率的危险因素之前,年龄较大的透析持续时间。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号